Patents by Inventor Ulrich Schaible

Ulrich Schaible has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUND
    Publication number: 20130157375
    Abstract: In one aspect, there is provided a fluorescent iron-binding compound bound to a solid phase. Also provided is a method for detecting non-transferrin bound iron in a sample, comprising contacting the sample with a fluorescent iron-binding compound bound to a solid phase and detecting a fluorescent signal derived from the fluorescent iron-binding compound bound to the solid phase, wherein the fluorescent signal is indicative of non-transferrin bound iron levels in the sample. Further provided is use of a fluorescent iron-binding compound bound to a solid phase to detect non-transferrin bound iron in a sample.
    Type: Application
    Filed: April 27, 2011
    Publication date: June 20, 2013
    Applicants: LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE, KING'S COLLEGE LONDON
    Inventors: Robert Hider, Yongmin Ma, Ulrich Schaible, Maria Podinovskaia
  • Identification of specific differentially expressed antigens
    Patent number: 7772386
    Abstract: The present invention relates to compositions useful in immunization against pathogenic organisms of the genus Mycobacterium and for diagnostic purposes. In particular, the present invention relates to a composition comprising at least one protein which is differentially expressed in a virulent strain as compared to an avirulent strain of Mycobacteria. Furthermore, the invention relates to compositions comprising fusion proteins, antigenic fragments, nucleic acid molecules encoding the aforementioned proteinaceous compounds and/or antibodies thereto. Additionally, the invention relates to pharmaceutical and diagnostic compositions comprising or employing compounds of the invention. In addition, the present invention relates to the use of the compounds of the invention for the treatment of Mycobacterium induced diseases and/or for the preparation of a vaccine for vaccination against Mycobacterium induced diseases.
    Type: Grant
    Filed: January 28, 2000
    Date of Patent: August 10, 2010
    Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.
    Inventors: Peter Jungblut, Stefan H. E. Kaufmann, Ulrich Schaible, Hans Mollenkopf, Bärbel Raupach, Ursula Zimny-Arndt, Stephanie Lamer, Jens Mattow
  • Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
    Patent number: 6676942
    Abstract: The invention related to novel Borrelia, and OspA antigens derived therefrom. These antigens show little homology with know OspA's and are therefore useful as vaccine and diagnostic reagents. Multicomponent vaccines based on OspA's from different Borrelia groups are also disclosed.
    Type: Grant
    Filed: April 1, 1999
    Date of Patent: January 13, 2004
    Assignees: SmithKline Beecham Biologicals (s.a.), Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V., Deutsches Krebs Forschungszentrum Stiftung des Offentlichen Rechts
    Inventors: Yves Lobet, Markus Simon, Ulrich Schaible, Reinhard Wallich, Michael Kramer
  • Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
    Patent number: 6113914
    Abstract: The invention relates to novel Borrelia, and OspA antigens derived therefrom. These antigens show little homology with known OspA's and are therefore useful as vaccine and diagnostic reagents. Multicomponent vaccines based on OspA's from different Borrelia groups are also disclosed.
    Type: Grant
    Filed: July 5, 1994
    Date of Patent: September 5, 2000
    Assignee: Smithkline Beecham Biologicals (S.A.)
    Inventors: Yves Lobet, Markus Simon, Ulrich Schaible, Reinhard Wallich, Michael Kramer
  • Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
    Patent number: 5942236
    Abstract: The invention relates to novet Borrelia, and OspA antigens derived therefrom. These antigens show little homology with known OspA's and are therefore useful as vaccine and diagnostic reagents. Multicomponent vaccines based on OspA's from different Borrelia groups are also disclosed.
    Type: Grant
    Filed: May 16, 1995
    Date of Patent: August 24, 1999
    Assignees: SmithKline Beecham Biologicals, Max-Planck-Gesellschaft zur Forderung der Wissenschafter e.V., Duetsches Krebsforschungszentrum Stiftung des offentlichen Rechts
    Inventors: Yves Lobet, Markus Simon, Ulrich Schaible, Reinhard Wallich, Michael Kramer